Igor Tsigelny, PhD

Igor originally developed the CureMatch technology while serving as Research Professor at the Department of Neurosciences, San Diego Supercomputer Center, and Moore’s Cancer Center (MCC). He is a member of the Molecular Tumor Board of the MCC, and is a recognized expert in molecular mechanisms of disease, structural biology, molecular modeling, bioinformatics and structure-based drug design.

Dr. Tsigelny has authored over 200 papers in peer-reviewed journals including Nature, Science, and Proceedings of National Academy of Sciences. He has designed three drug-candidates—aimed at Parkinson’s disease, brain cancer, and hypertension—which have all been licensed by UCSD to pharmaceutical companies and are in various stages of development.